- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01780129
Polydatin Injectable (HW6) for Shock Treatment (PIST)
A Randomized, Double-Blind, Placebo Controlled, Parallel Group Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HW6 in the Treatment of Traumatic/Hemorrhagic Shock and Septic Shock
HW6 can prolong animal's survival time and increase the survival rate. HW6 enhances cardiac function, improves microcirculation, and increases blood pressure and pulse pressure, and improves blood perfusion of important organs; HW6's anti-shock activity comes from a combined multiple target pharmacological effects.
Based on a completed phase II trial conducted in China, HW6 can effectively treatment shock patient.
This is a phase II clinical study to further evaluate the efficacy and safety of Polydatin Injectable 100mg/5mL/via (HW6) in the treatment of shock in the United States. Patients with traumatic/hemorrhagic shock or septic shock admitted to the emergency room or ICU with systolic blood pressure < 90mmHg, or is on vasopressor(s) for systolic blood pressure stabilization, regardless the types of completed, on-going, or projected Standard of Care or surgery will be recruited to participant in the trial. A total of 120 patients with traumatic/hemorrhagic shock and 120 patients with septic shock will be enrolled. For each type of shock, sixty patients each will be in test group and control group. Both adult males and females aged 18-80 years are eligible. The primary clinical endpoint is the time length (TL) between the start of HW6 administration to the onset of the first treatment success, that is: the systolic blood pressure is stabilized at ≥90mmHg and MAP≥65mmHg for 1 hour without the use of vasopressors. Several secondary endpoints and biomarkers will be measured.
Efficacy data will be compared using group t-test or Wilcoxon log-rank test between treatment groups and placebo groups. Safety data will also be reported accordingly.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19718
- Christiana Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult males or females aged 18-80 years.
- Patients with traumatic/hemorrhagic shock or septic shock admitted to the emergency room or ICU with systolic blood pressure < 90mmHg, or is on vasopressor(s) for systolic blood pressure stabilization, regardless the types of completed, ongoing, or projected Standard of Care or surgery.
- Patients (or its relative) who have signed Informed Consent Form to voluntarily participate in this clinical study.
Exclusion Criteria:
- Has known allergic constitution or history of alcohol or drug allergy. or
- Complicating acute cardiac failure, acute renal failure, acute liver failure or disseminated intravascular coagulation (DIC). or
- Pregnant or lactating women. or
- Complicating moderate to severe craniocerebral injury. or
- Has known previous severe chronic disease(s) in liver, kidney, carvascualr system or central nervous system. or
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Polydatin Injectable (HW6)
10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v.
infusion over 2 hours; once daily for 5 consecutive days
|
Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v.
infusion over 2 hours.
The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
Other Names:
|
PLACEBO_COMPARATOR: HW6 blank dummy (0.9%NaCl)
10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v.
infusion over 2 hours; once daily for 5 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time length (TL) between the start of HW6 administration to the onset of the first TS.
Time Frame: From the start of drug administration to the onset of TS (OTS) where the first systolic blood pressure≥90mmHg and MAP≥65mmHg is observed in the 7 consecutive measures
|
Treatment success (TS): the systolic blood pressure is stabilized at ≥90mmHg and MAP≥65mmHg for 1 hour without the use of vasopressor(s). Blood pressure will be recorded every 10 min. Treatment success is considered to have been achieved when 7 consecutive systolic blood pressure to be≥90mmHg and MAP≥65mmHg. The TL is the time from the start of drug administration to the onset of TS (OTS) where the first systolic blood pressure≥90mmHg and MAP≥65mmHg is observed in the 7 consecutive measures. Blood pressure will be measured every hour after the TS. If blood pressure become unstable, standard care will be in practice. |
From the start of drug administration to the onset of TS (OTS) where the first systolic blood pressure≥90mmHg and MAP≥65mmHg is observed in the 7 consecutive measures
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The amount and duration of total vasopressor(s) used during this TL period
Time Frame: From the start of drug administration to the onset of TS (OTS) where the first systolic blood pressure≥90mmHg and MAP≥65mmHg is observed in the 7 consecutive measures
|
Observation period: From start of study drug treatment to OTS. Record the details of the use of vasopressor(s) during TL for each subject, including name of medication, infusion concentration and rate, and the duration of each concentration and rate being maintained. Duration of vasopressor(s) use: accurate to the minute, or by the cumulative time of each administration if used intermittently. Total dose of vasopressor(s):The total dose of each vasopressor. |
From the start of drug administration to the onset of TS (OTS) where the first systolic blood pressure≥90mmHg and MAP≥65mmHg is observed in the 7 consecutive measures
|
The degree of fluid dependence
Time Frame: from the start of testing drug to the OTS
|
from the start of testing drug to the OTS
|
|
Metabolic indicators
Time Frame: Within 6 days
|
Arterial blood lactate, lactate clearance, oxygen saturation mixed venous blood, blood gas levels
|
Within 6 days
|
Severity of organ dysfunction in the ICU
Time Frame: Daily during the administration stay after enrollment
|
Compare the changes in SOFA score during the administration stay between the two groups to assess the protective effect of the study drug on vital organs.
|
Daily during the administration stay after enrollment
|
Duration of ICU stay
Time Frame: The total time (in hours) of ICU admission from the day of administration to day 7 (7 days)
|
The total time (in hours) of ICU admission from the day of administration to day 7 (7 days)
|
|
28-day survival
Time Frame: From the end of drug administration to Day 28
|
From the end of drug administration to Day 28
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fluid intake and output volume
Time Frame: Every 24h for 5 days
|
Every 24h for 5 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: YU Lin, PhD, Neptunus Pharmaceuticals Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HW6-01-US (REGISTRY: Neptunus Pharmaceuticals, Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock, Septic
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
Clinical Trials on Polydatin Injectable
-
University of Roma La SapienzaRecruitingIrritable Bowel SyndromeItaly
-
Ain Shams UniversityRecruiting
-
Psoriasis Treatment Center of Central New JerseySun Pharmaceutical Industries LimitedUnknown
-
AbbVieRecruiting
-
Tang-Du HospitalRecruitingMyasthenia Gravis, GeneralizedChina
-
AllerganCompletedSoft Tissue AugmentationFrance
-
Merz North America, Inc.CompletedVolume Loss of the Jawline
-
Achieve Life SciencesCompletedBreast Neoplasms | Lung Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Pelvic NeoplasmsUnited States
-
Fayoum UniversityCompleted
-
Cook Group IncorporatedCompletedPeripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb IschemiaCzechia